MedTrace Logo

Leveraging Clinic to Promote Literacy in Young Children

NCT04752943 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 381

Last updated 2021-03-29

No results posted yet for this study

Summary

Our primary aim of this study is to assess the impact of an early literacy text messaging program (TipsByText, TbT) for parents of children between 3 to 4-years old during an office visit without access to preschool. To assess this aim, our objectives are to specifically assess (1) child literacy using the Phonological Awareness Literacy Screening Tool (PALS-PreK) and (2) caregiver involvement using the Parent Child Interactivity Scale (PCI) pre- and post-intervention, comparing with a control group not receiving the TipsByText intervention. A secondary outcome of this study is to compare trust among families that participate in the Tips by Text (TbT) Program with families that do not participate in TbT using the Trust Evaluation Scale. Children will complete the PALS-PreK and caregivers of the children will complete the PCI and Trust Evaluation Scales.

Conditions

  • Literacy

Interventions

OTHER

Tips By Text Messages

Texts sent to caregivers meant to increase parent child interaction around literacy, sent to participants 3 x a week for 7 months

Sponsors & Collaborators

Principal Investigators

  • Lisa J Chamberlain, MD, MPH · Stanford University

  • Janine Bruce, MPH, DrPH · Stanford University

  • Susanna Loeb, PhD · Brown University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-16
Primary Completion
2019-07-26
Completion
2019-07-26

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752943 on ClinicalTrials.gov